StreetInsider.com News Articles

Nyxoah SA (NYXH) PT Lowered to $7 at Piper Sandler

Wed, 13 May 2026 08:37:10 -0400

(Updated - May 13, 2026 8:37 AM EDT)

Piper Sandler analyst Adam Maeder lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $7.00 (from $9.00) while maintaining an Overweight rating.

The analyst commented: "Solid Q1; U.S. Momentum Building As Evidenced By FY26 Guide; This evening (5/12), NYXH reported 1Q net-revenue of €6.4M, which came in above our (€5.9M) estimate and the Street's (€6.1M) bogey. U.S. Genio launch appears to be progressing well with U.S. net-revenue up +25% q/q and consistent with company expectations. NYXH announced that it is now up to 91 active U.S. accounts and has 241 prior auths heading

Nyxoah SA (NYXH) PT Lowered to $7 at Piper Sandler

Wed, 13 May 2026 08:37:10 -0400

(Updated - May 13, 2026 8:37 AM EDT)

Piper Sandler analyst Adam Maeder lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $7.00 (from $9.00) while maintaining an Overweight rating.

Form 6-K Nyxoah SA For: May 12

Tue, 12 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260512/26477853.html

Form 6-K Nyxoah SA For: May 12

Tue, 12 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260512/26477853.html

Form 6-K Nyxoah SA For: May 12

Tue, 12 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260512/26477853.html

Stifel Downgrades Nyxoah SA (NYXH) to Hold

Tue, 12 May 2026 03:06:59 -0400

Stifel analyst Jonathan Block downgraded Nyxoah SA (NASDAQ: NYXH) from Buy to Hold with a price target of $5.00 (from $8.00).

The analyst comments: “Our Hold rating on Nyxoah is supported by what we view as a challenging U.S. HGNS market (due in part to challenging reimbursement dynamics), subdued physician diligence relative to prior checks, and what we view as an already difficult competitive environment becoming more difficult with impending market entrants (LivaNova).

Our $5 target price (previously $8) is based on a discounted cash flow (DCF) analysis, which employs an 11.5% discount rate and 2.0% terminal growth rate.”

For an analyst ratings

Stifel Downgrades Nyxoah SA (NYXH) to Hold

Tue, 12 May 2026 03:06:59 -0400

Stifel analyst Jonathan Block downgraded Nyxoah SA (NASDAQ: NYXH) from Buy to Hold with a price target of $5.00 (from $8.00).

Our $5 target price (previously $8) is based on a discounted cash flow (DCF) analysis, which employs an 11.5% discount rate and 2.0% terminal growth rate.”

For an analyst ratings

Nyxoah SA (NYXH) PT Lowered to $8 at Stifel

Fri, 10 Apr 2026 07:35:01 -0400

Stifel analyst Jonathan Block lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $8.00 (from $10.00) while maintaining a Buy rating.

The analyst commented, "Our Buy rating on Nyxoah is supported by the company's recent FDA approval of Genio and subsequent U.S. launch, and our robust prior ENT survey diligence, which suggests the company's Genio system is poised to capture share in the U.S. hypoglossal nerve stimulation market. Our $8 target price (previously $10) is based on a discounted cash flow (DCF) analysis, which employs an 11.5% discount rate and 2.0% terminal growth rate. Risks to our target price include:

Nyxoah SA (NYXH) PT Lowered to $8 at Stifel

Fri, 10 Apr 2026 07:35:01 -0400

Stifel analyst Jonathan Block lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $8.00 (from $10.00) while maintaining a Buy rating.

Form S-8 Nyxoah SA

Thu, 26 Mar 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260326/26224819.html

Form S-8 Nyxoah SA

Thu, 26 Mar 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260326/26224819.html

Form S-8 Nyxoah SA

Thu, 26 Mar 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260326/26224819.html

Form 20-F Nyxoah SA For: Dec 31

Thu, 26 Mar 2026 16:02:00 -0400

http://archive.fast-edgar.com/20260326/ANB2D22C8W22B2ZK222Q2CZZ8PBGH2W2Z282

Filed on: March 26, 2026

Form 20-F Nyxoah SA For: Dec 31

Thu, 26 Mar 2026 16:02:00 -0400

http://archive.fast-edgar.com/20260326/ANB2D22C8W22B2ZK222Q2CZZ8PBGH2W2Z282

Filed on: March 26, 2026

Form 20-F Nyxoah SA For: Dec 31

Thu, 26 Mar 2026 16:02:00 -0400

http://archive.fast-edgar.com/20260326/ANB2D22C8W22B2ZK222Q2CZZ8PBGH2W2Z282

Filed on: March 26, 2026

Nyxoah SA (NYXH) Reiterated at Overweight by Cantor Fitzgerald on US Commercialization

Mon, 23 Mar 2026 07:52:52 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $11.00 price target on Nyxoah SA (NASDAQ: NYXH).

The analyst commented, "We are maintaining our Overweight rating & $11 price target on NYXH as its 1st full quarter of U.S. commercialization drives our confidence in its product. We believe its successful U.S. launch positions it well to take share throughout 2026. Its pending ACCCESS study results (expected by management in late June 2026 / early July 2026) are a key catalyst that can pave another path for expansion in 2027. 2026 has multiple pathways to drive incremental investor confidence. We view

Nyxoah SA (NYXH) PT Lowered to $10 at Stifel

Fri, 20 Mar 2026 08:18:55 -0400

Stifel analyst Jonathan Block lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $10.00 (from $11.00) while maintaining a Buy rating.

Form 6-K Nyxoah SA For: Mar 19

Thu, 19 Mar 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260319/26193552.html

Form 6-K Nyxoah SA For: Mar 19

Thu, 19 Mar 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260319/26193552.html

Form 6-K Nyxoah SA For: Mar 19

Thu, 19 Mar 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260319/26193552.html

Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Wed, 11 Mar 2026 17:05:00 -0400